Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: Results from a randomized controlled trial

Madhav A. Namjoshi, Gopalan Rajamannar, Thomas Jacobs, Todd M. Sanger, Richard Risser, Mauricio F. Tohen, Alan Breier, Paul E. Keck

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Introduction: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania. Methods: Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. Results: During the acute phase, olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients. In the open label extension, patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy. These cost savings were largely driven by reductions in in-patient costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. Conclusion: From a clinical, economic, and quality-of-life outcomes standpoint, olanzapine had a significant impact in the treatment of mania, and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalJournal of Affective Disorders
Volume69
Issue number1-3
DOIs
StatePublished - 2002

Fingerprint

olanzapine
Bipolar Disorder
Randomized Controlled Trials
Economics
Quality of Life
Therapeutics
Costs and Cost Analysis
Cost Savings
Fluoxetine
Quality Improvement
Lithium
Health Care Costs
Population

Keywords

  • Direct medical costs
  • Mania
  • Olanzapine
  • Quality of life

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania : Results from a randomized controlled trial. / Namjoshi, Madhav A.; Rajamannar, Gopalan; Jacobs, Thomas; Sanger, Todd M.; Risser, Richard; Tohen, Mauricio F.; Breier, Alan; Keck, Paul E.

In: Journal of Affective Disorders, Vol. 69, No. 1-3, 2002, p. 109-118.

Research output: Contribution to journalArticle

Namjoshi, Madhav A. ; Rajamannar, Gopalan ; Jacobs, Thomas ; Sanger, Todd M. ; Risser, Richard ; Tohen, Mauricio F. ; Breier, Alan ; Keck, Paul E. / Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania : Results from a randomized controlled trial. In: Journal of Affective Disorders. 2002 ; Vol. 69, No. 1-3. pp. 109-118.
@article{3c780d18e17345018884eb9d8184ceb8,
title = "Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: Results from a randomized controlled trial",
abstract = "Introduction: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania. Methods: Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. Results: During the acute phase, olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients. In the open label extension, patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy. These cost savings were largely driven by reductions in in-patient costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. Conclusion: From a clinical, economic, and quality-of-life outcomes standpoint, olanzapine had a significant impact in the treatment of mania, and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.",
keywords = "Direct medical costs, Mania, Olanzapine, Quality of life",
author = "Namjoshi, {Madhav A.} and Gopalan Rajamannar and Thomas Jacobs and Sanger, {Todd M.} and Richard Risser and Tohen, {Mauricio F.} and Alan Breier and Keck, {Paul E.}",
year = "2002",
doi = "10.1016/S0165-0327(01)00310-X",
language = "English (US)",
volume = "69",
pages = "109--118",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania

T2 - Results from a randomized controlled trial

AU - Namjoshi, Madhav A.

AU - Rajamannar, Gopalan

AU - Jacobs, Thomas

AU - Sanger, Todd M.

AU - Risser, Richard

AU - Tohen, Mauricio F.

AU - Breier, Alan

AU - Keck, Paul E.

PY - 2002

Y1 - 2002

N2 - Introduction: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania. Methods: Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. Results: During the acute phase, olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients. In the open label extension, patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy. These cost savings were largely driven by reductions in in-patient costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. Conclusion: From a clinical, economic, and quality-of-life outcomes standpoint, olanzapine had a significant impact in the treatment of mania, and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.

AB - Introduction: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania. Methods: Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. Results: During the acute phase, olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients. In the open label extension, patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy. These cost savings were largely driven by reductions in in-patient costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. Conclusion: From a clinical, economic, and quality-of-life outcomes standpoint, olanzapine had a significant impact in the treatment of mania, and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.

KW - Direct medical costs

KW - Mania

KW - Olanzapine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0036018491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036018491&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(01)00310-X

DO - 10.1016/S0165-0327(01)00310-X

M3 - Article

C2 - 12103458

AN - SCOPUS:0036018491

VL - 69

SP - 109

EP - 118

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -